Mdwise Formulary Introduction – Healthy Indiana Plan Basic (HIP Basic)

Total Page:16

File Type:pdf, Size:1020Kb

Mdwise Formulary Introduction – Healthy Indiana Plan Basic (HIP Basic) MDwise Formulary Introduction – Healthy Indiana Plan Basic (HIP Basic) HIP members must use MDwise network pharmacies to access their prescription drug benefit. How do I use the formulary? There are two ways to find your drug within the formulary: Medical Condition Drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category “Cardiovascular Disease”. Then look under the category name for your drug. Alphabetical Listing The Index provides an alphabetical list of all of the drugs included in this formulary. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list. The formulary provides coverage information about drugs covered by the plan. If you have trouble finding your drug in the list, turn to the Index. All drugs are listed by their generic names and most common proprietary (branded) name. The Formulary may be accessed by using the Index, either by generic or proprietary name or by therapeutic drug category. In situations where an FDA-approved generic equivalent is available, brand names are listed for reference purposes only, and do not denote coverage for the brand name, unless specifically noted. All drugs are listed in each category in alphabetical order by generic name. Where an FDA-approved generic is available for the listed generic name, the generic name is bolded. A generic drug has the same active-ingredient as the brand name drug. Generic drugs usually cost less than brand name drugs and are approved by the Food and Drug Administration (FDA), which assures that the following conditions are met. • The generic drug must contain the same active ingredients, be the same strength, and the same dosage form as the brand name drug. • The FDA has given an “A” rating compared to the brand name drug and thus the generic drug is determined to be therapeutically bioequivalent. • When the above two criteria are met, a generic can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product. Additional Requirements Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include: • Prior Authorization: MDwise requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from the pharmacy benefits manager (MedImpact) before you fill your prescription. If you don’t get approval, the drug may not be covered. Drugs that are subject to a prior authorization will have a “PA” symbol next to the drug. Physicians and Pharmacies call (844) 336-2677 or FAX: (858) 790-7100. • Quantity Limits: For certain drugs, the plan limits the amount of the drug that is covered. Drugs that are subject to a quantity limit will have a “QL” symbol next to the drug. • Refill Limitations: Prescriptions may be refilled when 75% or more of the days’ supply has been used. • Step Therapy: In some cases, the plan requires you to first try certain drugs to treat your medical condition before it will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. Drugs that are subject to Step Therapy will have a “ST” symbol next to the drug. • Age Limit: In some cases, drugs are only available to a member in a select age category. Drugs that are subject to an Age Limit will have an “AGE” symbol next to the drug. • Gender Limit: Some drugs are only available to members of a certain gender. Drugs that are available to only a certain gender will have a “G” symbol next to the drug. You can find out if your drug has any additional requirements or limits by looking in the formulary starting on the next page. If you have any additional questions, please visit our website at mdwise.org or contact the customer service center at (844) 336-2677. Table of Contents Allergy....................................................................................................................................................................................... 3 Antiemesis/Antivertigo...............................................................................................................................................................6 Asthma And Copd..................................................................................................................................................................... 6 Autonomic Nervous System Disorders................................................................................................................................... 11 Behavioral Health - Antidepressants.......................................................................................................................................12 Behavioral Health - Other........................................................................................................................................................14 Cardiovascular Disease - Arrhythmia......................................................................................................................................23 Cardiovascular Disease - Cardiac Stimulant...........................................................................................................................23 Cardiovascular Disease - Hypertension..................................................................................................................................23 Cardiovascular Disease - Lipid Irregularity............................................................................................................................. 27 Cardiovascular Disease - Miscellaneous Agents.................................................................................................................... 35 Cardiovascular Disease - Vasodilation................................................................................................................................... 35 Contraception/Oxytocics......................................................................................................................................................... 36 Cough And Cold......................................................................................................................................................................41 Dermatology - Acne................................................................................................................................................................ 51 Dermatology - Antiinfective..................................................................................................................................................... 53 Dermatology - Antiinflammatory..............................................................................................................................................57 Dermatology - Antipruritic Drugs............................................................................................................................................. 60 Dermatology - Miscellaneous..................................................................................................................................................60 Dermatology - Pigmentation Disorders................................................................................................................................... 72 Dermatology - Psoriasis/Eczema............................................................................................................................................ 72 Diabetes.................................................................................................................................................................................. 74 Ear - General Disorders.......................................................................................................................................................... 80 Electrolyte Regulation............................................................................................................................................................. 81 Endocrine Disorder - Fertility...................................................................................................................................................83 Endocrine Disorder - Other..................................................................................................................................................... 83 Endocrine Disorder - Thyroid.................................................................................................................................................. 86 Eye - General Disorders..........................................................................................................................................................87 Eye - Glaucoma...................................................................................................................................................................... 89 Eye - Miscellaneous...............................................................................................................................................................
Recommended publications
  • Pharmaceutical Sciences
    IAJPS 2017, 4 (08), 2671 - 2680 V.L.Sravani et al ISSN 2349 - 7750 CODEN [USA]: IAJPBB ISSN: 2349 - 7750 I N D O A M E R I C A N J O U R N A L O F P H A R M A C E U T I C A L S C I E N C E S Available online at: http://www.iajps.com Research Article ANTI - ACNE ACTIVITY OF LIPIDO - STEROLIC EXTRACT OF SERENOA REPENS AND HYDRO - ALCOHOLIC EXTRACT OF GLYCYRRHIZA GLABRA IN SYRIAN HAMSTER EAR MODEL V. Laxmi Sravani 1 *, Dr. B. Ch a n drasekhar Rao 1 , Dr. D. Ravi Krishna Babu 2 1 Department of Pharma cology, RGR Siddhanthi College of Pharmacy , Secundera bad. 2 Aurigene Discovery Technologies Pvt Ltd. Miyapur, Hyderabad. Abstract : Acne vulgaris is the most commonly encountered dermatological disease of pilosebaceous unit. Androgens, which increase during puberty, stimulate the sebaceous gland to produce sebum and cause retention of keratinocytes around the sebaceous hair follicle orifice causing partial to complete blockage and leading to colonization with Propionibacterium acnes, which participates in the production of pro inflammatory mediators. For treatment of acne one of the approaches is to reduce sebum production, the main stimulus to acne; then all other pathogenic factors will diminish. A comprehensive approach combining the natural medicine with anti - androgenic activity would be fruitful area for anti - acne therapy. In this context the well documented anti - androgenic herbs like liquorice and saw palmetto were selected and screened in Syrian hamster ear model using spironolactone as standard.
    [Show full text]
  • Updates in Pediatric Dermatology
    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
    [Show full text]
  • Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, Or Psoriasis: a Review of Clinical and Cost- Effectiveness
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost- Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: September 25, 2017 Report Length: 19 Pages Authors: Raywat Deonandan, Melissa Severn Cite As: Pimecrolimus for the treatment of adults with atopic dermatitis, seborrheic dermatitis, or psoriasis: a review of clinical and cost- effectiveness. Ottawa: CADTH; 2017 Sep. (CADTH rapid response report: summary with critical appraisal). Acknowledgments: ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron
    THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron. All Rights Reserved. Health For Every Man Over 30 The Prostate Problem Like women, men too are exposed to the effects of chemical estrogens in their environment. In addition, as their testosterone levels drop with age, there is, in many cases, a concomitant rise in estradiol levels -- the major reason that many older men develop breasts. Just as with women, estradiol stimulates cell growth in men too and is potentially cancerous. Estradiol stimulates the BCL2 gene, which is the gene responsible for stopping cell death. What at first glance sounds like a positive, is, upon closer inspection, not. When cell death in prostate tissue, for example, is blocked, cell growth continues unabated -- becoming a major contributing factor in the enlargement of the prostate and the development of prostate cancer. This is one of the main factors involved in the dramatically increased incidence of prostate cancer. • A new case of Prostate Cancer is diagnosed every 3 minutes in America and every 15 minutes a man dies from prostate cancer. • Prostate Cancer is the second leading type of cancer among men. • 11 million men have some form of Prostate Cancer in the United States. • African-American men have the highest rate of Prostate Cancer in the world. • Survival rates for men with prostate cancer in 1995 were no different than they were in 1965. • The age at which Prostate Cancer develops will drop ten years by the year 2000. By the year 2000, Prostate Cancer will increase by 90%. The Prostate Solution Regular use of a men's progesterone crememakes a great deal of sense for any man over the age of 30.
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • Pimecrolimus Cream 1% PI
    Mat# 238328-01 Filename: 238328-01_PimecroCrm30gPi_5_18.indd Proof# 1 Artist Name/Date: Mike Aspinall 9/10/18 AMT Version: 10 Sep 2018 Vault# VV-141752 Approvals:* NDA/ANDA# 209345 Black Approval: Date: Approval: Date: ” n/a Rev: * Applicable when approver is not able to apply electronic signature to PDF in Veeva Vault or Acrobat® Electronic and scanned proxy approval signatures appear on separate pages following the proof pages within this PDF Iss. 5/2018 n/a Created by: Outsert Configuration: Regulatory Affairs US Artwork Management Team Flat: 10” x 27” 1070 Horsham Road, North Wales, PA, 19454 Phone 215-591-3000 Fold: 5” x 2.25” Die Line - No Print 10” 10.00 1/8” 5” 5” 2.25” .25” 238328-01 238328-01 Pimecrolimus Cream Pimecrolimus Cream Rx only Rx only 238328-01 238328-01 Iss. 5/2018 Iss. 5/2018 HIGHLIGHTS OF PRESCRIBING INFORMATION • If signs and symptoms persist beyond 6 weeks, patients should be 8 USE IN SPECIFIC POPULATIONS These highlights do not include all the information needed to use re-examined. (2) 8.1 Pregnancy PIMECROLIMUS CREAM safely and effectively. See full prescribing • Continuous long-term use of pimecrolimus cream, 1% should be Pregnancy Category C information for PIMECROLIMUS CREAM. avoided. (2) There are no adequate and well-controlled studies with pimecrolimus cream, 1% in pregnant women. Therefore, pimecrolimus cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. PIMECROLIMUS cream, 1% for topical use • Avoid use with occlusive dressings. (2) Initial U.S. Approval: 2001 In dermal embryofetal developmental studies, no maternal or fetal toxicity was observed up to the highest practicable doses tested, 10 mg/kg/day DOSAGE FORMS AND STRENGTHS ”2 (1% pimecrolimus cream) in rats (0.14X MRHD based on body surface area) and 10 mg/kg/day (1% pimecrolimus cream) in rabbits (0.65X MRHD WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN Cream, 1%.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • The 5ARI Withdrawal Syndrome (5ARI-WS)
    The 5ARI Withdrawal Syndrome (5ARI-WS) The Silenced Androgen Receptor (AR) Theory: Explaining persistent side effects arising from 5alpha reductase (5AR) inhibitor (5ARI) use By “Awor” and “Mew”, Administrators of Propeciahelp.com (July 2010) 1. Introduction An increasingly overwhelming amount of evidence is starting to accumulate from various doctors, scientists, patient groups and online discussion forums, whereby seemingly unrelated substances such as finasteride, dutasteride, isotretinoin and saw palmetto extract (SPE) based preparations are causing young consumers to suffer from long-term, irreversible and serious health damage. The experienced persistent side effect have a clear denominator in that they all seem to relate to physiological and psychological functions which require androgens to function correctly: Loss of libido (1) (2) Low energy, fatigue (1) Depression (including suicidal depression)* (3) (4) (5) (6) Impaired thought processes* (7) Memory failure* (7) Erectile dysfunction (8) (9) (2) Penile atrophy (9) Impaired spermatogenesis (10) (11) (12) Muscle wasting (13) (14) (15) Gynecomastia (16) Dry skin and dry eyes (17) (18) (19) Prostate problems (2) Metabolic syndrome (20) Osteoporosis (21) (22) Anxiety and sleep disorders, muscle spasms (23) (24) (25) * Indirect action through 3α-HSD as described later in this document Of substantial note is that most side effects typically surface or reach full extent roughly 10-14 days after quitting the 5ARI substances. Androgen dependent tissue atrophy (penile, scrotum,
    [Show full text]
  • Beta-Sitosterol [BSS] and Betasitosterol Glucoside [BSSG] As an Adjuvant in the Treatment of Pulmonary Tuberculosis Patients.” TB Weekly (4 Mar 1996)
    Saw Palmetto (Serenoa repens) and One of Its Constituent Sterols -Sitosterol [83-46-5] Review of Toxicological Literature Prepared for Errol Zeiger, Ph.D. National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, North Carolina 27709 Contract No. N01-ES-65402 Submitted by Raymond Tice, Ph.D. Integrated Laboratory Systems P.O. Box 13501 Research Triangle Park, North Carolina 27709 November 1997 EXECUTIVE SUMMARY The nomination of saw palmetto and -sitosterol for testing is based on the potential for human exposure and the limited amount of toxicity and carcinogenicity data. Saw palmetto (Serenoa repens), a member of the palm family Arecaceae, is native to the West Indies and the Atlantic Coast of North America, from South Carolina to Florida. The plant may grow to a height of 20 feet (6.10 m), with leaves up to 3 feet (0.914 m) across. The berries are fleshy, about 0.75 inch (1.9 cm) in diameter, and blue-black in color. Saw palmetto berries contain sterols and lipids, including relatively high concentrations of free and bound sitosterols. The following chemicals have been identified in the berries: anthranilic acid, capric acid, caproic acid, caprylic acid, - carotene, ferulic acid, mannitol, -sitosterol, -sitosterol-D-glucoside, linoleic acid, myristic acid, oleic acid, palmitic acid, 1-monolaurin and 1-monomyristin. A number of other common plants (e.g., basil, corn, soybean) also contain -sitosterol. Saw palmetto extract has become the sixth best-selling herbal dietary supplement in the United States. In Europe, several pharmaceutical companies sell saw palmetto-based over-the-counter (OTC) drugs for treating benign prostatic hyperplasia (BPH).
    [Show full text]
  • Baus Section of Oncology the British Prostate Group
    Prostate Cancer and Prostatic Diseases (2006 ) 9, 310 –335 & 2006 Nature Publishing Group All rights reserved 1365-7852/06 $30.00 www.nature.com/pcan BAUS SECTION OF ONCOLOGY THE BRITISH PROSTATE GROUP PROSTATE CANCER – A MEETING OF MINDS FINAL ABSTRACTS Manchester International Convention Centre 24th – 26th November 2004 Abstracts British Prostate Group Does increasing the number of cores of prostate biopsy Anorectal dysfunction after 3-D conformal radiotherapy for 311 improve diagnostic accuracy? Indications and morbidity localised prostate cancer Kapasi F, Chandrasekar P, Barber C, Samman R, Dickon Hayne, Nula Allen, Dan Ashdown, Amanda Mellon, Potluri B and Virdi J. John Glaholm, Mike Foster Good Hope Hospital, Birmingham, Methods A study was conducted on accurate data maintained on 400 Introduction: patients who underwent transrectal ultrasound (TRUS) guided Previous work (Ref 1, 2) has shown a very high incidence of prostate biopsy. Patients were divided into three groups anorectal side effects with associated changes on anorectal depending on the number of cores and each group was physiology following conventional radiotherapy for localised subdivided into two based on the PSA level (PSA<20 & prostate cancer (CaP). We report early results on the first PSA>20). TRUS biopsy procedure was carried out using B and prospective study aiming to identify symptoms and quantify K medical ultrasound scanner no. 2002 (Panther Unit) using anorectal dysfunction after 3-D conformal radiotherapy (3D- Biplanor rectal probe (8551). An 18G, 20cm biopsy needle CRT) for CaP. (Biopty gun) was used. Patients & methods: Intravenous Gentamicin 120mg, Metronidazole 500mg Ethical approval was obtained from the North Birmingham suppository given at the time of procedure, followed by oral Regional Ethics Committee.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
    [Show full text]